Mirtacen for dogs 3,75 mg 10 tablets 
- Highly effective:
It belongs to the new generation of drugs
It is eff ective for appetite disorders of any origin
Safe:
Low hazard class (belongs to Class 4)
In recommended doses, it does not have embryotoxic, teratogenic and sensitizing effects
Easy to administer:
It is available in two concentrations (1.88 mg; 3.75 mg)
Wide dosage ranges
Available without a veterinarian’s prescription
A drug for correcting eating behavior
MIRTACEN® is used for eating disorders in dogs and cats associated with decreased appetite of various etiologies, including chronic
kidney disease and chemotherapy
MIRTACEN® contains mirtazapine as an active ingredient. The drug is produced in two dosages with the content of mirtazapine in each tablet: 1.88 mg; 3.75 mg. As excipients, it contains microcrystalline cellulose, sodium croscarmellose, calcium stearate, colloidal silicon dioxide, aspasvite C 200, lactose monohydrate.
MIRTACEN® is administered orally to dogs, forcibly on the root of the tongue 1 time a day, regardless of food intake.
Cats are administered orally, forcibly on the root of the tongue 1 time in 24-48 hours, regardless of food intake. Cats with kidney and liver pathologies are administered orally, forcibly on the root of the tongue 1 time in 48-72 hours, regardless of food intake.
| Animal weight | |||
| Cats, regardless of body weight | 1 tablet | - | |
| Dogs* | < 3 kg | 1 tablet | - |
| 3-5 kg | 2 tablets | 1 tablet | |
| 5-10 kg | - | 2 tablets | |
| 10-20 kg | - | - | |
The doses and duration of the course are selected individually, depending on the reason for prescribing the drug, tolerability and the degree of the eff ect. The recommended dose should be titrated to the lowest eff ective for stimulating appetite.
After stopping taking MIRTACEN®, it is important to monitor the animal’s food intake. After discontinuation of the drug, food intake may decrease.
If the feed intake decreases sharply (> 75%) within a few days or if the animal completely refuses to feed for more than 48 hours, consult a veterinarian.
Contraindication to use is individual intolerance to the components of the drug. There is no data on the use of the drug in females during pregnancy and lactation, its eff ect on the fed animal is unknown, therefore, milk feeding should be discontinued during treatment. If necessary, the drug is used under the supervision of a veterinarian based on an assessment of the ratio of the expected benefi t to the possible risk of its use.
The drug is stored in a closed manufacturer’s packaging, in a place protected from direct sunlight, separate from food and feed at a
temperature from 2 °C to 25 °C. MYRTACENE® should be stored in places inaccessible to children.
The shelf life of the medicinal product, subject to storage conditions in the manufacturer’s closed packaging, is 2 years from the date of manufacture.
Quality and product control -
guarantee for our customers
customers and their pets
